PBI29 ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP): EUROPEAN REGULATORY FRAMEWORK COMPARED TO GERMANY [PDF]
E. Mueller, K. Neeser, I.B. Oelze
openaire +1 more source
Legal pathways to optimize access to Advanced Therapy Medicinal Products (ATMP)
Advanced therapy medicinal products (ATMP), although offering considerable medical advances, are not accessible to patients because of their high prices. Managed entry agreements (MEA), particularly performance-based agreements (PbA), are an interesting way of facilitating access to these treatments while controlling the financial risk involved in ...
openaire +1 more source
Advanced therapy medicinal products in Saudi Arabia: Regulation and development. [PDF]
AlMuhanna MH +9 more
europepmc +1 more source
Advanced Therapy Medicinal Products (ATMPs) in the light of precision (personalized) medicine
openaire +1 more source
Regulatory Convergence in Cell and Gene Therapy: Harmonizing Quality, CMC, and Approval Pathways Across the FDA, EMA, PMDA, and Emerging Markets. [PDF]
Verma N, Arora S.
europepmc +1 more source
Expanding Patient Access to Advanced Therapies. [PDF]
Guillen E, Hidalgo-Simon A.
europepmc +1 more source
Engineering the future of advanced therapy medicinal products: a bioengineering call to action. [PDF]
Nieri G +4 more
europepmc +1 more source
The in vivo revolution in CAR-T therapy medicinal products: challenges and regulatory prospects. [PDF]
Lu J +7 more
europepmc +1 more source
Regulatory approach to manipulated organs in Europe: preserving human organs as non-commercial goods. [PDF]
Cuende N, Izeta A, DomÃnguez-Gil B.
europepmc +1 more source
PBI35 HEALTH ECONOMICS MODELLING FOR ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP): A TARGETED LITERATURE REVIEW (LR) [PDF]
I. Agirrezabal +3 more
openaire +1 more source

